News & Insights
OIC Associate Hector Edwards Discusses Medtech Financing Risk and Rewards in the FT’s PWM
A historical cycle of scarcity and survival presents an opportunity for outsized returns in the often misunderstood medical technology investment market.
At OIC we believe that the most compelling opportunities often lie where others hesitate—especially in the middle stages of med-tech innovation. As highlighted in a recent Professional Wealth Management piece by our associate Hector Edwards, the “missing middle” refers to the technologically de-riskeed but pre-commercial phase of medical technology companies: the phase where regulatory, reimbursement and commercial adoption hurdles converge. The full article can be found on Professional Wealth Management.
Why this segment matters
-
After the funding boom for med-tech ended in 2021, companies without commercial proof points struggled far more than those nearing market.
-
Whilst there has been a recovery in medtech funding, the first half of 2025 is already tracking to be the sector’s best funding year since the boom; allocation is disproportionately skewed to later-stage, commercial companies.
-
The “missing middle” is where transformative devices (for example surgical robotics or advanced diagnostics) move from lab prototypes into the clinic — and this is precisely where outsized value creation can be found.
If you’re interested in learning more about med-tech investing and how the “missing middle” fits into our strategy, feel free to contact us for a conversation.